Login / Signup

Retinal biomarkers and pharmacological targets for Hermansky-Pudlak syndrome 7.

Giovanni Luca RomanoChiara Bianca Maria PlataniaGian Marco LeggioSebastiano Alfio TorrisiSalvatore GiuntaSalvatore SalomoneMichele PurrelloMarco RagusaCristina BarbagalloFrank J GiblinRosa MastrogiacomoFrancesca ManagòMaurizio CammalleriFrancesco PapaleoFilippo DragoClaudio Bucolo
Published in: Scientific reports (2020)
Deletion of dystrobrevin binding protein 1 has been linked to Hermansky-Pudlak syndrome type 7 (HPS-7), a rare disease characterized by oculocutaneous albinism and retinal dysfunction. We studied dysbindin-1 null mutant mice (Dys-/-) to shed light on retinal neurodevelopment defects in HPS-7. We analyzed the expression of a focused set of miRNAs in retina of wild type (WT), Dys+/- and Dys-/- mice. We also investigated the retinal function of these mice through electroretinography (ERG). We found that miR-101-3p, miR-137, miR-186-5p, miR-326, miR-382-5p and miR-876-5p were up-regulated in Dys-/-mice retina. Dys-/- mice showed significant increased b-wave in ERG, compared to WT mice. Bioinformatic analysis highlighted that dysregulated miRNAs target synaptic plasticity and dopaminergic signaling pathways, affecting retinal functions of Dys-/- mice. Overall, the data indicate potential mechanisms in retinal neurodevelopment of Dys-/- mice, which may have translational significance in HSP-7 patients, both in terms of diagnostic/prognostic biomarkers and novel pharmacological targets.
Keyphrases